精准医学与心血管疾病预防：聚焦炎症与脂质，我们在 2019 年处于什么位置？
PRECISION MEDICINE FOR CARDIOVASCULAR DISEASE PREVENTION: WHERE DO WE STAND IN 2019 WITH A FOCUS ON INFLAMMATION AND LIPIDS?
机构信息
HOUSTON, TEXAS.
出版信息
Trans Am Clin Climatol Assoc. 2020;131:42-47.
Abstract
In this manuscript, I will discuss where we stand in 2019, with a focus on inflammation and lipids, in regard to precision medicine for cardiovascular disease prevention. This manuscript will reflect my career journey working in the cardiovascular disease field.
摘要
在本文中，我将讨论我们在 2019 年的立场，重点是炎症和脂质，关于心血管疾病预防的精准医学。本文将反映我在心血管疾病领域工作的职业历程。
相似文献
1
PRECISION MEDICINE FOR CARDIOVASCULAR DISEASE PREVENTION: WHERE DO WE STAND IN 2019 WITH A FOCUS ON INFLAMMATION AND LIPIDS?精准医学与心血管疾病预防：聚焦炎症与脂质，我们在 2019 年处于什么位置？
Trans Am Clin Climatol Assoc. 2020;131:42-47.
2
Precision Medicine and a Patient-Orientated Approach: Is this the Future for Tracking Cardiovascular Disorders?精准医学与以患者为导向的方法：这会是追踪心血管疾病的未来方向吗？
Curr Pharm Des. 2017;23(6):889-893. doi: 10.2174/1381612822666161006124400.
3
[Laboratory medicine, my philosophy and prospect].
Rinsho Byori. 1993 Jan;41(1):47-51.
4
Perspectives from a Pathologist: My Journey on the Path to Women's Health Research, Sex and Gender Policy, and Practice Implications.病理学家的视角：我在女性健康研究、性别政策以及实践影响方面的探索历程。
Annu Rev Pathol. 2018 Jan 24;13:1-25. doi: 10.1146/annurev-pathol-020117-044020.
5
From the Swimming Pool to Precision Cardiovascular Physical Therapy: What a Journey!从游泳池到精准心血管物理治疗：这是一段怎样的旅程！
Cardiopulm Phys Ther J. 2024 Sep 25;35(4):126-134. doi: 10.1097/CPT.0000000000000260. eCollection 2024 Oct.
6
Repetitive on-demand drug release from polymeric matrices containing a macroscopic spherical iron core.具有宏观球形铁核的聚合物基质中药物的重复按需释放。
J Mater Sci Mater Med. 2017 Sep 15;28(10):163. doi: 10.1007/s10856-017-5983-7.
7
Applying Precision Medicine to Healthy Living for the Prevention and Treatment of Cardiovascular Disease.将精准医学应用于健康生活以预防和治疗心血管疾病。
Curr Probl Cardiol. 2018 Dec;43(12):448-483. doi: 10.1016/j.cpcardiol.2018.06.001. Epub 2018 Jun 14.
8
Precision Medicine and Personalized Medicine in Cardiovascular Disease.精准医学与心血管疾病个体化医学
Adv Exp Med Biol. 2018;1065:589-605. doi: 10.1007/978-3-319-77932-4_36.
9
Mistakes Made and Lessons Learned: A Mid-Career Pediatric Orthopaedic Surgeon's Journey to Sustain Energy and Avoid Burnout.
J Pediatr Orthop. 2020 Jul;40 Suppl 1:S16-S21. doi: 10.1097/BPO.0000000000001488.
10
Personalized Herbal Medicine? A Roadmap for Convergence of Herbal and Precision Medicine Biomarker Innovations.个性化草药医学？草药和精准医学生物标志物创新融合的路线图。
OMICS. 2018 Jun;22(6):375-391. doi: 10.1089/omi.2018.0074.
本文引用的文献
1
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.依泽替米贝降低严重高甘油三酯血症患者心血管风险
N Engl J Med. 2019 Jan 3;380(1):11-22. doi: 10.1056/NEJMoa1812792. Epub 2018 Nov 10.
2
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.卡那单抗抑制白细胞介素-1β对动脉粥样硬化患者肺癌发病的影响：一项随机、双盲、安慰剂对照试验的探索性结果。
Lancet. 2017 Oct 21;390(10105):1833-1842. doi: 10.1016/S0140-6736(17)32247-X. Epub 2017 Aug 27.
3
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.卡那奴单抗治疗动脉粥样硬化疾病的抗炎疗法。
N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27.
4
The Upregulation of Integrin αβ (CD11d/CD18) on Inflammatory Macrophages Promotes Macrophage Retention in Vascular Lesions and Development of Atherosclerosis.炎症巨噬细胞上整合素αβ（CD11d/CD18）的上调促进巨噬细胞在血管病变中的滞留及动脉粥样硬化的发展。
J Immunol. 2017 Jun 15;198(12):4855-4867. doi: 10.4049/jimmunol.1602175. Epub 2017 May 12.
5
Dyslipidaemia: PCSK9 inhibitors and foamy monocytes in familial hypercholesterolaemia.血脂异常：家族性高胆固醇血症中的 PCSK9 抑制剂和泡沫单核细胞。
Nat Rev Cardiol. 2017 Jul;14(7):385-386. doi: 10.1038/nrcardio.2017.75. Epub 2017 May 11.
6
CD11c/CD18 Signals Very Late Antigen-4 Activation To Initiate Foamy Monocyte Recruitment during the Onset of Hypercholesterolemia.CD11c/CD18信号激活极迟抗原-4，以在高胆固醇血症发作期间启动泡沫单核细胞募集。
J Immunol. 2015 Dec 1;195(11):5380-92. doi: 10.4049/jimmunol.1501077. Epub 2015 Oct 30.
7
Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease.载脂蛋白 C-III 与甘油三酯：在动脉粥样硬化性心血管疾病中的关联、机制和治疗靶点
J Am Coll Cardiol. 2014 Dec 16;64(23):2525-40. doi: 10.1016/j.jacc.2014.09.042.
8
Common variants associated with plasma triglycerides and risk for coronary artery disease.与血浆甘油三酯相关的常见变异体与冠心病风险。
Nat Genet. 2013 Nov;45(11):1345-52. doi: 10.1038/ng.2795. Epub 2013 Oct 6.
9
Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).依泽替米贝（AMR101）治疗他汀类药物治疗后持续性高甘油三酯血症患者的疗效和安全性（来自 ANCHOR 研究）。
Am J Cardiol. 2012 Oct 1;110(7):984-92. doi: 10.1016/j.amjcard.2012.05.031. Epub 2012 Jul 20.
10
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.更强化降低 LDL 胆固醇的疗效和安全性：来自 26 项随机试验中 170000 名参与者数据的荟萃分析。
Lancet. 2010 Nov 13;376(9753):1670-81. doi: 10.1016/S0140-6736(10)61350-5. Epub 2010 Nov 8.
Zotero 插件